Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2015 Sep 1;16(9):20704-30.
doi: 10.3390/ijms160920704.

Mitochondria: A Therapeutic Target for Parkinson's Disease?

Affiliations
Review

Mitochondria: A Therapeutic Target for Parkinson's Disease?

Yu Luo et al. Int J Mol Sci. .

Abstract

Parkinson's disease (PD) is one of the most common neurodegenerative disorders. The exact causes of neuronal damage are unknown, but mounting evidence indicates that mitochondrial-mediated pathways contribute to the underlying mechanisms of dopaminergic neuronal cell death both in PD patients and in PD animal models. Mitochondria are organized in a highly dynamic tubular network that is continuously reshaped by opposing processes of fusion and fission. Defects in either fusion or fission, leading to mitochondrial fragmentation, limit mitochondrial motility, decrease energy production and increase oxidative stress, thereby promoting cell dysfunction and death. Thus, the regulation of mitochondrial dynamics processes, such as fusion, fission and mitophagy, represents important mechanisms controlling neuronal cell fate. In this review, we summarize some of the recent evidence supporting that impairment of mitochondrial dynamics, mitophagy and mitochondrial import occurs in cellular and animal PD models and disruption of these processes is a contributing mechanism to cell death in dopaminergic neurons. We also summarize mitochondria-targeting therapeutics in models of PD, proposing that modulation of mitochondrial impairment might be beneficial for drug development toward treatment of PD.

Keywords: Parkinson’s disease; mitochondrial dynamics; mitochondrial dysfunction.

PubMed Disclaimer

References

    1. Duvoisin R.C. Overview of Parkinson’s disease. Ann. N. Y. Acad. Sci. 1992;648:187–193. doi: 10.1111/j.1749-6632.1992.tb24537.x. - DOI - PubMed
    1. Dauer W., Przedborski S. Parkinson’s disease: Mechanisms and models. Neuron. 2003;39:889–909. doi: 10.1016/S0896-6273(03)00568-3. - DOI - PubMed
    1. Dawson T.M., Dawson V.L. Molecular pathways of neurodegeneration in Parkinson’s disease. Science. 2003;302:819–822. doi: 10.1126/science.1087753. - DOI - PubMed
    1. Yao Z., Wood N.W. Cell death pathways in Parkinson’s disease: Role of mitochondria. Antioxid. Redox Signal. 2009;11:2135–2149. doi: 10.1089/ars.2009.2624. - DOI - PubMed
    1. Ellis C.E., Murphy E.J., Mitchell D.C., Golovko M.Y., Scaglia F., Barcelo-Coblijn G.C., Nussbaum R.L. Mitochondrial lipid abnormality and electron transport chain impairment in mice lacking alpha-synuclein. Mol. Cell. Biol. 2005;25:10190–10201. doi: 10.1128/MCB.25.22.10190-10201.2005. - DOI - PMC - PubMed

MeSH terms

LinkOut - more resources